Recent investigations on retatrutides, a dual activator for incretin hormone and gastric inhibitory polypeptide, suggest promising outcomes in managing weight gain and type 2 diabetic condition. Early data from clinical trials reveal considerable decreases in body bulk and bettered glucose regula